메뉴 건너뛰기




Volumn 81, Issue 4, 2011, Pages

Gleason Pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation

Author keywords

Gleason Pattern 5; Gleason score; Prostate cancer; Radiation therapy; Stratification

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CAUSE-SPECIFIC SURVIVAL; CLINICAL FAILURE; CLINICAL OUTCOME; COMORBID ILLNESS; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON PATTERN 5; GLEASON SCORES; HAZARD RATIO; LOCALIZED PROSTATE CANCER; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PLANNING TARGET VOLUMES; PRE-TREATMENT; PROGNOSTIC FACTORS; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RISK FACTORS; RISK STRATIFICATION; SYSTEMIC THERAPY;

EID: 80255137088     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.01.063     Document Type: Article
Times cited : (66)

References (50)
  • 1
    • 0034817278 scopus 로고    scopus 로고
    • Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience
    • DOI 10.1016/S0094-0143(05)70163-4
    • M. Han, A. Partin, and C. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565 (Pubitemid 32916759)
    • (2001) Urologic Clinics of North America , vol.28 , Issue.3 , pp. 555-565
    • Han, M.1    Partin, A.W.2    Pound, C.R.3    Epstein, J.I.4    Walsh, P.C.5
  • 3
    • 0033787042 scopus 로고    scopus 로고
    • Prognostic significance of Gleason score 3+ 4 versus Gleason score 4+ 3 tumor at radical prostatectomy
    • T. Chan, A. Partin, and P. Walsh Prognostic significance of Gleason score 3+ 4 versus Gleason score 4+ 3 tumor at radical prostatectomy Urology 56 2000 823 827
    • (2000) Urology , vol.56 , pp. 823-827
    • Chan, T.1    Partin, A.2    Walsh, P.3
  • 4
    • 0030025610 scopus 로고    scopus 로고
    • Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up
    • DOI 10.1097/00000478-199603000-00004
    • J. Epstein, A. Partin, and J. Sauvageot Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 20 1996 286 292 (Pubitemid 26071509)
    • (1996) American Journal of Surgical Pathology , vol.20 , Issue.3 , pp. 286-292
    • Epstein, J.I.1    Partin, A.W.2    Sauvageot, J.3    Walsh, P.C.4
  • 6
    • 0034268588 scopus 로고    scopus 로고
    • External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era
    • A. Pollack, L. Smith, and A. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
    • (2000) Int J Radiat Oncol Biol Phys , vol.48 , pp. 507-512
    • Pollack, A.1    Smith, L.2    Von Eschenbach, A.3
  • 7
    • 0031022948 scopus 로고    scopus 로고
    • A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma
    • DOI 10.1002/(SICI)1097-0142(19970115)79:2<337::AID-CNCR17>3.0.CO;2- 1
    • T. Pisansky, M. Kahn, and G. Rasp A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma Cancer 79 1997 337 344 (Pubitemid 27029898)
    • (1997) Cancer , vol.79 , Issue.2 , pp. 337-344
    • Pisansky, T.M.1    Kahn, M.J.2    Rasp, G.M.3    Cha, S.S.4    Haddock, M.G.5    Bostwick, D.G.6
  • 8
    • 77649158894 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer
    • J. Mohler, R. Bahnson, and B. Boston National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer J Natl Compr Canc Neww 8 2010 162 200
    • (2010) J Natl Compr Canc Neww , vol.8 , pp. 162-200
    • Mohler, J.1    Bahnson, R.2    Boston, B.3
  • 9
    • 67651122848 scopus 로고    scopus 로고
    • Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials
    • A. Nanda, M. Chen, and A. Renshaw Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials Int J Radiat Oncol Biol Phys 74 2009 1419 1423
    • (2009) Int J Radiat Oncol Biol Phys , vol.74 , pp. 1419-1423
    • Nanda, A.1    Chen, M.2    Renshaw, A.3
  • 10
    • 70449334526 scopus 로고    scopus 로고
    • Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy
    • R. Stock, J. Cesaretti, and S. Hall Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy BJU Int 104 2009 1631 1636
    • (2009) BJU Int , vol.104 , pp. 1631-1636
    • Stock, R.1    Cesaretti, J.2    Hall, S.3
  • 11
    • 35648964767 scopus 로고    scopus 로고
    • Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy
    • DOI 10.1002/cncr.23004
    • L. Cheng, D. Davidson, and H. Lin Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy Cancer 110 2007 1967 1972 (Pubitemid 350036855)
    • (2007) Cancer , vol.110 , Issue.9 , pp. 1967-1972
    • Cheng, L.1    Davidson, D.D.2    Lin, H.3    Koch, M.O.4
  • 12
    • 19444364960 scopus 로고    scopus 로고
    • The combined percentage of gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy
    • DOI 10.1200/JCO.2005.03.018
    • L. Cheng, M. Koch, and B. Juliar The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy J Clin Oncol 23 2005 2911 2917 (Pubitemid 46224109)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.13 , pp. 2911-2917
    • Cheng, L.1    Koch, M.O.2    Juliar, B.E.3    Daggy, J.K.4    Foster, R.S.5    Bihrle, R.6    Gardner, T.A.7
  • 13
    • 33847302011 scopus 로고    scopus 로고
    • The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    • D. D'Ambrosio, A. Hanlon, and T. Al-Saleem The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1082 1087
    • (2007) Int J Radiat Oncol Biol Phys , vol.67 , pp. 1082-1087
    • D'Ambrosio, D.1    Hanlon, A.2    Al-Saleem, T.3
  • 15
    • 33847148917 scopus 로고    scopus 로고
    • Should We Replace the Gleason Score with the Amount of High-Grade Prostate Cancer?
    • DOI 10.1016/j.eururo.2006.07.051, PII S0302283806008918
    • A. Vis, S. Roemeling, and R. Kranse Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol 51 2007 931 939 (Pubitemid 46281411)
    • (2007) European Urology , vol.51 , Issue.4 , pp. 931-939
    • Vis, A.N.1    Roemeling, S.2    Kranse, R.3    Schroder, F.H.4    Van Der Kwast, T.H.5
  • 16
    • 79952701542 scopus 로고    scopus 로고
    • Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: Who dies of disease?
    • In press
    • Kuban D, Levy L, Cheung M, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: Who dies of disease? Int J Radiat Oncol Biol Phys. In press.
    • Int J Radiat Oncol Biol Phys
    • Kuban, D.1    Levy, L.2    Cheung, M.3
  • 18
    • 33745184874 scopus 로고    scopus 로고
    • Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    • M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
    • (2006) Int J Radiat Oncol Biol Phys , vol.65 , pp. 965-974
    • Roach III, M.1    Hanks, G.2    Thames Jr., H.3
  • 19
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
    • DOI 10.1016/0021-9681(87)90171-8
    • M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
    • (1987) Journal of Chronic Diseases , vol.40 , Issue.5 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.A.3    MacKenzie, C.R.4
  • 20
    • 77950968988 scopus 로고    scopus 로고
    • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    • T.K. Choueiri, M.H. Chen, and A.V. D'Amico Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death Cancer 116 2010 1887 1892
    • (2010) Cancer , vol.116 , pp. 1887-1892
    • Choueiri, T.K.1    Chen, M.H.2    D'Amico, A.V.3
  • 21
    • 37049031020 scopus 로고    scopus 로고
    • Interval to Biochemical Failure Highly Prognostic for Distant Metastasis and Prostate Cancer-Specific Mortality After Radiotherapy
    • DOI 10.1016/j.ijrobp.2007.05.047, PII S0360301607009777
    • M.K. Buyyounouski, A.L. Hanlon, and E.M. Horwitz Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66 (Pubitemid 350251025)
    • (2008) International Journal of Radiation Oncology Biology Physics , vol.70 , Issue.1 , pp. 59-66
    • Buyyounouski, M.K.1    Hanlon, A.L.2    Horwitz, E.M.3    Pollack, A.4
  • 22
    • 70449708045 scopus 로고    scopus 로고
    • Measuring time to biochemical failure in the TROG 96.01 trial: When should the clock start ticking?
    • J.W. Denham, A. Steigler, and M. Kumar Measuring time to biochemical failure in the TROG 96.01 trial: When should the clock start ticking? Int J Radiat Oncol Biol Phys 75 2009 1008 1012
    • (2009) Int J Radiat Oncol Biol Phys , vol.75 , pp. 1008-1012
    • Denham, J.W.1    Steigler, A.2    Kumar, M.3
  • 23
    • 54349113978 scopus 로고    scopus 로고
    • Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial
    • J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
    • (2008) Lancet Oncol , vol.9 , pp. 1058-1068
    • Denham, J.W.1    Steigler, A.2    Wilcox, C.3
  • 25
    • 59649091159 scopus 로고    scopus 로고
    • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors
    • P.L. Nguyen, M.H. Chen, and W.J. Catalona Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors Intt J Radiat Oncol Biol Phys 73 2009 659 664
    • (2009) Intt J Radiat Oncol Biol Phys , vol.73 , pp. 659-664
    • Nguyen, P.L.1    Chen, M.H.2    Catalona, W.J.3
  • 26
    • 58149327450 scopus 로고    scopus 로고
    • Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
    • N. Stone, L. Potters, and B. Davis Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341 346
    • (2009) Int J Radiat Oncol Biol Phys , vol.73 , pp. 341-346
    • Stone, N.1    Potters, L.2    Davis, B.3
  • 27
    • 1642576015 scopus 로고    scopus 로고
    • The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer
    • DOI 10.1002/cncr.11927
    • R. Jacob, A.L. Hanlon, and E.M. Horwitz The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer Cancer 100 2004 538 543 (Pubitemid 38124771)
    • (2004) Cancer , vol.100 , Issue.3 , pp. 538-543
    • Jacob, R.1    Hanlon, A.L.2    Horwitz, E.M.3    Movsas, B.4    Uzzo, R.G.5    Pollack, A.6
  • 29
    • 34250862630 scopus 로고    scopus 로고
    • Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    • DOI 10.1002/cncr.22755
    • P.B. Morgan, A.L. Hanlon, and E.M. Horwitz Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy Cancer 110 2007 68 80 (Pubitemid 46986420)
    • (2007) Cancer , vol.110 , Issue.1 , pp. 68-80
    • Morgan, P.B.1    Hanlon, A.L.2    Horwitz, E.M.3    Buyyounouski, M.K.4    Uzzo, R.G.5    Pollack, A.6
  • 30
    • 60049090809 scopus 로고    scopus 로고
    • Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial
    • J.M. Crook, S. Malone, and G. Perry Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial Cancer 115 2009 673 679
    • (2009) Cancer , vol.115 , pp. 673-679
    • Crook, J.M.1    Malone, S.2    Perry, G.3
  • 31
    • 0036662309 scopus 로고    scopus 로고
    • Gleason score predicts androgen independent progression after androgen deprivation therapy
    • DOI 10.1016/S0302-2838(02)00238-5, PII S0302283802002385
    • E. Benaim, C. Pace, and C. Roehrborn Gleason score predicts androgen independent progression after androgen deprivation therapy Eur Urol 42 2002 12 17 (Pubitemid 35339640)
    • (2002) European Urology , vol.42 , Issue.1 , pp. 12-17
    • Benaim, E.A.1    Pace, C.M.2    Roehrborn, C.G.3
  • 32
    • 80255124425 scopus 로고    scopus 로고
    • A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, extramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902
    • Chicago, IL
    • Sandler HM, Hunt D, Sartor AO, et al. A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, extramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. The 2010 ASCO Annual Meeting. Chicago, IL; 2010.
    • (2010) The 2010 ASCO Annual Meeting
    • Sandler, H.M.1    Hunt, D.2    Sartor, A.O.3
  • 33
    • 75949124984 scopus 로고    scopus 로고
    • Treatment strategies for high-risk locally advanced prostate cancer
    • S.A. Rosenthal, and H.M. Sandler Treatment strategies for high-risk locally advanced prostate cancer Nat Rev Urol 7 2010 31 38
    • (2010) Nat Rev Urol , vol.7 , pp. 31-38
    • Rosenthal, S.A.1    Sandler, H.M.2
  • 35
    • 67149125847 scopus 로고    scopus 로고
    • Duration of androgen suppression in the treatment of prostate cancer
    • M. Bolla, T. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
    • (2009) N Engl J Med , vol.360 , pp. 2516-2527
    • Bolla, M.1    De Reijke, T.2    Van Tienhoven, G.3
  • 36
    • 45149105820 scopus 로고    scopus 로고
    • Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
    • E. Horwitz, K. Bae, and G. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
    • (2008) J Clin Oncol , vol.26 , pp. 2497-2504
    • Horwitz, E.1    Bae, K.2    Hanks, G.3
  • 38
    • 65549123613 scopus 로고    scopus 로고
    • Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31
    • L. Souhami, K. Bae, and M. Pilepich Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31 J Clin Oncol 27 2009 2137 2143
    • (2009) J Clin Oncol , vol.27 , pp. 2137-2143
    • Souhami, L.1    Bae, K.2    Pilepich, M.3
  • 39
    • 58649103315 scopus 로고    scopus 로고
    • Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial
    • A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial Lancet 373 2009 301 308
    • (2009) Lancet , vol.373 , pp. 301-308
    • Widmark, A.1    Klepp, O.2    Solberg, A.3
  • 40
    • 34147174524 scopus 로고    scopus 로고
    • Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer
    • D.M. Kube, C.D. Savci-Heijink, and A.F. Lamblin Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer BMC Mol Biol 8 2007 25
    • (2007) BMC Mol Biol , vol.8 , pp. 25
    • Kube, D.M.1    Savci-Heijink, C.D.2    Lamblin, A.F.3
  • 45
    • 77954255681 scopus 로고    scopus 로고
    • Integrative genomic profiling of human prostate cancer
    • Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell;18:11-22.
    • Cancer Cell , vol.18 , pp. 11-22
    • Taylor, B.S.1    Schultz, N.2    Hieronymus, H.3
  • 47
    • 18744371597 scopus 로고    scopus 로고
    • The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy
    • DOI 10.1097/01.ju.0000158155.33890.e7
    • M. Cooperberg, D. Pasta, and E. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942 (Pubitemid 40675216)
    • (2005) Journal of Urology , vol.173 , Issue.6 , pp. 1938-1942
    • Cooperberg, M.R.1    Pasta, D.J.2    Elkin, E.P.3    Litwin, M.S.4    Latini, D.M.5    Duchane, J.6    Carroll, P.R.7
  • 48
    • 0032950295 scopus 로고    scopus 로고
    • Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
    • M. Kattan, T. Wheeler, and P. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507 (Pubitemid 29220858)
    • (1999) Journal of Clinical Oncology , vol.17 , Issue.5 , pp. 1499-1507
    • Kattan, M.W.1    Wheeler, T.M.2    Scardino, P.T.3
  • 49
    • 0034287457 scopus 로고    scopus 로고
    • Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
    • M. Kattan, M. Zelefsky, and P. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
    • (2000) J Clin Oncol , vol.18 , pp. 3352-3359
    • Kattan, M.1    Zelefsky, M.2    Kupelian, P.3
  • 50
    • 27244432751 scopus 로고    scopus 로고
    • Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
    • A. Stephenson, P. Scardino, and J. Eastham Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012
    • (2005) J Clin Oncol , vol.23 , pp. 7005-7012
    • Stephenson, A.1    Scardino, P.2    Eastham, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.